Two Japanese reports indicated that IFN-β treatment was not effective in reducing the relapse number and the disability progression, and concluded that IFN-β treatment does not appear to be effective for preventing relapse in NMO, likely due to differences in the immune-pathogenesis between NMO and MS [23], [24]. This evidence concerns the gene IFNB1 and myeloid sarcoma.